替罗非班治疗急性缺血性卒中的应用进展
发布时间：2018-12-14 05:30
【摘要】：正卒中已成为世界第二大致死原因和第三大致残原因,其中缺血性卒中占80%~([1-3])。而在急性缺血性卒中发病机制中,血小板活化在导致血栓形成,并进一步阻塞血管致缺血事件中起着非常重要的作用。因此,选择性快速抑制血小板聚集非常关键,不但能够起到溶解血栓作用,且能够预防血栓再次形成~([4])。替罗非班是一种选择性非肽类血小板糖蛋白Ⅱb/Ⅲa受体拮抗剂,能通过与血小板表面Ⅱb/Ⅲa受体结合,阻断其与纤维蛋白原配体特异性结合,从
[Abstract]:Positive stroke has become the second leading cause of death and the third major cause of disability in the world, in which ischemic stroke accounts for 80 ~ (1-3). In the pathogenesis of acute ischemic stroke, platelet activation plays a very important role in thrombosis and further occlusion of vascular ischemic events. Therefore, selective and rapid inhibition of platelet aggregation is crucial, not only to dissolve thrombus, but also to prevent thrombus from reforming. Tirofiban is a selective non-peptide platelet glycoprotein 鈪，
本文编号：2378017
[Abstract]:Positive stroke has become the second leading cause of death and the third major cause of disability in the world, in which ischemic stroke accounts for 80 ~ (1-3). In the pathogenesis of acute ischemic stroke, platelet activation plays a very important role in thrombosis and further occlusion of vascular ischemic events. Therefore, selective and rapid inhibition of platelet aggregation is crucial, not only to dissolve thrombus, but also to prevent thrombus from reforming. Tirofiban is a selective non-peptide platelet glycoprotein 鈪，
本文编号：2378017
本文链接：https://www.wllwen.com/yixuelunwen/jjyx/2378017.html
最近更新
教材专著
